Literature DB >> 1940803

Identification of C3 beta chain as the human serum eosinophil cytotoxicity inhibitor.

M S Minkoff1, W W Wong, D S Silberstein.   

Abstract

An eosinophil cytotoxicity inhibitor (ECI) was purified from serum of a human subject with severe allergic dermatitis. Molecular weight of the isolated polypeptide (75,000) and its NH2-terminal amino acid sequence identified it as the beta chain of the C3 complement component (apparently free, but perhaps attached to very small fragments of the alpha chain). Free beta chain, prepared from normal plasma by reduction of C3, inhibited both eosinophil cytotoxicity and neutrophil adherence functions, with half-maximal activity at approximately 250 ng/ml. Apparently free C3 beta chain was detected in certain human biological fluids associated with inflammation; the presence of C3 beta chain correlated with ECI activity. This evidence demonstrates a potential role for free C3 beta chain as a suppressor of eosinophil and neutrophil functions in inflammation.

Entities:  

Mesh:

Substances:

Year:  1991        PMID: 1940803      PMCID: PMC2118984          DOI: 10.1084/jem.174.5.1267

Source DB:  PubMed          Journal:  J Exp Med        ISSN: 0022-1007            Impact factor:   14.307


  12 in total

1.  A serum factor that suppresses the cytotoxic function of cytokine-stimulated human eosinophils.

Authors:  D S Silberstein; M S Minkoff; A A Creasey; J R David
Journal:  J Exp Med       Date:  1990-03-01       Impact factor: 14.307

2.  The ability of mouse monoclonal antibodies to direct the cytotoxic function of cytokine-activated human eosinophils.

Authors:  D S Silberstein; J R David; D A Harn
Journal:  Hybridoma       Date:  1990-06

3.  Human complement component C3: cDNA coding sequence and derived primary structure.

Authors:  M H de Bruijn; G H Fey
Journal:  Proc Natl Acad Sci U S A       Date:  1985-02       Impact factor: 11.205

Review 4.  Membrane complement receptors specific for bound fragments of C3.

Authors:  G D Ross; M E Medof
Journal:  Adv Immunol       Date:  1985       Impact factor: 3.543

5.  A new method for the purification of human eosinophils and neutrophils, and a comparison of the ability of these cells to damage schistosomula of Schistosoma mansoni.

Authors:  M A Vadas; J R David; A Butterworth; N T Pisani; T A Siongok
Journal:  J Immunol       Date:  1979-04       Impact factor: 5.422

6.  Human eosinophil- and neutrophil-mediated killing of schistosomula of Schistosoma mansoni in vitro. I. Enhancement of complement-dependent damage by mast cell-derived mediators and formyl methionyl peptides.

Authors:  A R Anwar; J R McKean; S R Smithers; A B Kay
Journal:  J Immunol       Date:  1980-03       Impact factor: 5.422

7.  Complement-dependent histaminase release from human granulocytes.

Authors:  J J Herman; I K Rosner; A E Davis; R S Zeiger; M A Arnaout; H R Colten
Journal:  J Clin Invest       Date:  1979-06       Impact factor: 14.808

8.  Complement (C3b) interaction with the human granulocyte receptor: correlation of binding of fluid-phase radiolabeled ligand with histaminase release.

Authors:  J Melamed; M A Arnaout; H R Colten
Journal:  J Immunol       Date:  1982-05       Impact factor: 5.422

9.  Tumor necrosis factor enhances eosinophil toxicity to Schistosoma mansoni larvae.

Authors:  D S Silberstein; J R David
Journal:  Proc Natl Acad Sci U S A       Date:  1986-02       Impact factor: 11.205

10.  Isolation of a fragment (C3a) of the third component of human complement containing anaphylatoxin and chemotactic activity and description of an anaphylatoxin inactivator of human serum.

Authors:  V A Bokisch; H J Müller-Eberhard; C G Cochrane
Journal:  J Exp Med       Date:  1969-05-01       Impact factor: 14.307

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.